Form 4: Agios Pharmaceuticals Director Rahul Ballal Reports Acquisition of Restricted Stock Units and Stock Options

Director Rahul Ballal reports acquisition of restricted stock units and stock options in Agios Pharmaceuticals.

Summary

• On June 20, 2024, Rahul D. Ballal, a director of Agios Pharmaceuticals, acquired 2,120 restricted stock units (RSUs) and 11,774 stock options.
• The RSUs will vest on June 20, 2025, and each unit represents a contingent right to receive one share of Agios Pharmaceuticals' common stock.
• The stock options, also granted on June 20, 2024, vest as to 100% of the underlying shares on June 20, 2025, and expire on June 20, 2034.
• The exercise price for the stock options is $42.45.
• Following these transactions, Ballal directly owns 2,120 RSUs and 11,774 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports routine insider transactions. The acquisition of stock options and restricted stock units by a director can be seen as a positive sign, but it's a common occurrence.

Positives

• The acquisition of RSUs and stock options by a director signals confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and equity ownership of company directors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment as it indicates a director's investment in the company.

Key Dates